High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management

(2016) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients

(2016) Mahnur Haider et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis

(2016) Yu-Qing Pei et al.   ANNALS OF HEMATOLOGY

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

(2016) A. Kaifie et al.   Journal of Hematology & Oncology

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists

(2016) V De Stefano et al.   LEUKEMIA

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients

(2016) V De Stefano et al.   Blood Cancer Journal

Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

(2015) Juan-Carlos Hernández-Boluda et al.   ANNALS OF HEMATOLOGY

Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study

(2015) Malin Hultcrantz et al.   JOURNAL OF CLINICAL ONCOLOGY

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)

(2014) Stephan Kreher et al.   ANNALS OF HEMATOLOGY

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

(2014) M C Finazzi et al.   LEUKEMIA

Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: A physician survey

(2014) Martin H. Ellis et al.   THROMBOSIS RESEARCH

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

(2013) H. Gisslinger et al.   BLOOD

Splanchnic vein thrombosis in myeloproliferative neoplasms

(2013) Mallika Sekhar et al.   BRITISH JOURNAL OF HAEMATOLOGY

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venous thromboembolism: Epidemiology and magnitude of the problem

(2012) Samuel Z. Goldhaber   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

(2012) Roberto Marchioli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

(2011) A. Carobbio et al.   BLOOD

Splanchnic vein thrombosis: clinical presentation, risk factors and treatment

(2010) Valerio De Stefano et al.   Internal and Emergency Medicine

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Thrombosis in primary myelofibrosis: incidence and risk factors

(2009) T. Barbui et al.   BLOOD

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review

(2009) Federico Lussana et al.   THROMBOSIS RESEARCH

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

(2008) V. De Stefano et al.   HAEMATOLOGICA